Fig. 1: Progression-free survival (PFS) and overall survival (OS) analyses. | Nature Communications

Fig. 1: Progression-free survival (PFS) and overall survival (OS) analyses.

From: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Fig. 1: Progression-free survival (PFS) and overall survival (OS) analyses.The alternative text for this image may have been generated using AI.

a PFS according to study arm, b PFS according to TP53 status, c PFS according to IGHV mutational status, d OS according to study arm, e multivariable analyses of PFS in Ven-Obi arm (n = 194) and f in Clb-Obi arm (n = 179); horizontal bars in e and f represent 95% confidence intervals of hazard ratios (indicated by squares) with the vertical lines representing a hazard ratio of 1.0.

Back to article page